DNA Repair Drugs Market Players:
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- GlaxoSmithKline Plc.
- Bayer Ag
- Bristol-Myers Squibb Co.
- Pfizer Inc.
- Sanofi
- Eli Lilly And Co.
- Amgen Inc.
- Abbott
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Novartis Ag
- Nerviano Medical Sciences S.r.l.
The DNA repair drugs market is competitive due to the existence of industry giants and the entrance of new companies. The key market players are adopting strategies such as collaborations and partnerships to introduce innovative therapeutic solutions and increase their market reach. Collaboration with research organizations is one of the investment-worthy tactics widely adopted by leading companies. New companies are concentrated on introducing advanced and latest DNA repair cancer drugs. Such moves are widely adopted by start-ups to stand out from the crowd.
Some of the key players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of DNA repair drugs is evaluated at USD 9.76 billion.
The global DNA repair drugs market size exceeded USD 8.65 billion in 2025 and is set to register a CAGR of over 14.2%, exceeding USD 32.63 billion revenue by 2035.
North America’s DNA repair drugs market is anticipated to capture 47.5% share by 2035, driven by rising burden of cancer and increasing investments in DNA repair drugs R&D.
Key players in the market include Pfizer Inc., AstraZeneca plc, Merck & Co., Inc., GlaxoSmithKline plc, Onxeo S.A., Kura Oncology, Inc., Clovis Oncology, Inc., Tesaro, Inc. (GSK), Sierra Oncology, Inc., Artios Pharma Limited.
